Verge Genomics & Alexion collaborate for AI-Enabled Drug Discovery

Verge to receive up to $42M in upfront and near-term payments, with future cumulative milestones worth up to $840M

The collaboration is the second with a leading global pharmaceutical company and shows the unique scalability of the CONVERGE™ platform for technology-enabled drug discovery

Verge Genomics, a clinical-stage biotechnology company transforming drug discovery using artificial intelligence (AI) and patient tissue data, today announced a multi-target collaboration with Alexion, AstraZeneca Rare Disease (“Alexion”) to identify novel drug targets for rare neurodegenerative and neuromuscular diseases. Under the terms of the four-year agreement, Verge will receive up to $42 million, consisting of upfront fee, equity, and near-term payments, with a potential deal value of $840 million plus potential downstream royalties.

“By leveraging Verge’s AI-enabled platform in combination with data from patient tissue samples, we see potential in helping researchers more efficiently identify and validate therapeutic targets for rare diseases,” said Seng H. Cheng, Senior Vice President, Head of Research and Product Development, Alexion. “This collaboration will contribute to Alexion’s science-led innovation and may help accelerate our efforts to transform the discovery and development of new medicines for patients with rare disease.”

The collaboration, which is Verge’s second with a leading global pharmaceutical company, will leverage CONVERGE™, a full-stack platform that combines highly predictive human tissue datasets with machine learning to find new targets with a higher probability of clinical success. Instead of starting with cell or animal models, Verge’s drug discovery platform is based on a proprietary library of genomic datasets derived directly from human tissue that is coupled with an advanced human-centered biology platform to rapidly advance new data insights into clinical candidates. This approach, validated through the successful advancement of Verge’s lead program in amyotrophic lateral sclerosis (ALS), will be used to identify novel therapeutic targets. Alexion will select high-potential targets for each indication, with the option to license and advance successful targets through clinical development and commercialization.

“Our collaboration with Alexion is a tremendous opportunity to leverage the combined power of CONVERGE’s technology-enabled approach to drug discovery with Alexion’s expertise in developing and commercializing rare disease treatments,” said Jane Rhodes, Chief Business Officer, Verge Genomics. “We believe that our work with Alexion will build on our achievements in CNS drug discovery and is indicative of the sustained interest from pharma in the potential of AI to transform drug discovery and development.”

Alongside this collaboration agreement, AstraZeneca will take an equity position in Verge Genomics, building upon Verge’s strong roster of industry-leading strategic investors that include Eli Lilly and Merck Global Health Innovation Fund.

Previous ArticleNext Article

Leave a Reply

Your email address will not be published. Required fields are marked *